Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
β-lactamase Inhibitor
Brobactam sodium is a potent synthetic β-lactamase inhibitor that effectively targets various β-lactamase enzymes. This compound exhibits broad-spectrum antibacterial activity, making it a valuable tool for enhancing the efficacy of β-lactam antibiotics. Brobactam sodium is primarily utilized in research applications aimed at understanding antibiotic resistance mechanisms and developing new therapeutic strategies against resistant bacterial strains. -
Bacterial Inhibitor
3-CPs is a serotype capsular polysaccharide that inhibits antibody-mediated bacterial killing. By interfering with the immune response, it effectively reduces the phagocytosis of encapsulated bacteria. This compound is valuable for studying bacterial pathogenesis and the mechanisms of immune evasion. 3-CPs can inform research on vaccine development and therapeutic strategies aimed at combating encapsulated bacterial infections. -
Heat-inactivated Bacterial Luciferases Inhibitor
2-Nonanone is a ketone compound that inhibits the DnaKJE-ClpB bichaperone-dependent refolding of heat-inactivated bacterial luciferases. By interacting with hydrophobic segments of heat-inactivated substrates, it competes with chaperones such as IbpAB. This compound is valuable for research into bacterial infections and the mechanisms of chaperone-mediated protein refolding. -
Parasite Inhibitor
Hydroxymetronidazole, a metabolite of Metronidazole, functions primarily as an inhibitor of parasitic infections. This nitroimidazole derivative exhibits significant antibacterial and antiprotozoal activities, making it valuable in research applications related to bacterial and protozoal diseases. It is particularly useful for studying conditions such as swine dysentery, as well as genital trichomoniasis in cattle, contributing to a better understanding of these veterinary health issues. -
Bacterial Inhibitor
Ethyl Orsellinate is a lichen-derived metabolite and a derivative of lecanoric acid, primarily acting as a bacterial inhibitor. It exhibits notable antiproliferative and antitumor activities, making it useful in cancer research. The compound demonstrates significant cytotoxicity against A. salina, with an LC50 of 495 μM, indicating its potential as a bioactive agent in the study of microbial and tumor biology. -
Bacterial Inhibitor
EcMetAP1-IN-1 is a selective inhibitor of Escherichia coli methionine aminopeptidase 1 (MetAP1), a key enzyme involved in protein maturation. By obstructing the enzymatic activity of MetAP1, this compound effectively disrupts bacterial growth and protein synthesis, making it a valuable tool for research focused on bacterial infections and antibiotic development. Its specificity towards MetAP1 further positions EcMetAP1-IN-1 as a potential candidate for studying the mechanistic roles of methionine aminopeptidases in pathogenic bacteria. -
Bacterial Inhibitor
Urolithin M6 is a polyphenolic compound primarily recognized for its role as a bacterial inhibitor. This metabolite, synthesized through intestinal microbial metabolism, exhibits potential antioxidant properties and may function as an analogue to tannic acid compounds. Urolithin M6's production in humans necessitates the presence of specific bacterial 3-dehydroxylase activity, unveiling a novel pathway for its biotransformation. The metabolic profile of Urolithin M6 can aid in stratifying individuals for research aimed at elucidating its implications in health and disease. -
Bacterial Inhibitor
Methyl octanoate acts as a bacterial inhibitor and is recognized for its role in antimicrobial activity. This compound has applications in food preservation and can be studied for its effects on microbial growth inhibition. Additionally, it serves as a volatile aroma component in various beverages, including persimmon wine, making it of interest in both food science and microbiology research. -
Bacterial Inhibitor
NSC-79887 is a potent nucleoside hydrolase inhibitor that demonstrates significant activity against Bacillus anthracis. This compound serves as a promising candidate for biological testing and further development aimed at countering bacterial infections. Additionally, its pharmacokinetic profile suggests that all physicochemical parameters fall within acceptable ranges, indicating potential suitability for human use. -
Bacterial Inhibitor
Surgumycin is a bacterial inhibitor that exhibits notable antimicrobial activity. Its mechanism involves disrupting essential cellular processes in bacteria, making it a valuable tool for studying bacterial infections and resistance mechanisms. Surgumycin is particularly useful in research applications focused on antibiotic development and the exploration of microbial pathogenesis. -
Bacterial Inhibitor
LL-BM123α is a bacterial inhibitor derived from Nocardia sp., with a primary mechanism of action targeting Gram-negative bacteria. This compound demonstrates moderate antimicrobial activity, making it a valuable tool in research focused on bacterial infections and antibiotic resistance. LL-BM123α can be utilized in studies aimed at understanding the efficacy of novel antibiotics and developing strategies for overcoming bacterial resistance. -
Antibacterial, Biofilm Formation Inhibitor
Majoranaquinone is a potent antibacterial agent that targets various bacterial strains, demonstrating significant inhibitory effects against four Staphylococcus species, one Moraxella species, and one Enterococcus species. Additionally, it exhibits substantial efflux pump inhibitory activity in Escherichia coli ATCC 25922. Majoranaquinone also effectively inhibits biofilm formation in both E. coli ATCC 25922 and E. coli K-12 AG100, making it a valuable reagent for research applications focused on combating bacterial infections and biofilm-related challenges. -
Bacterial Inhibitor
Lauryl-LF 11 is an N-terminally acylated analogue of LF11 that acts as a bacterial inhibitor. This peptide demonstrates significant antibacterial activity, making it a valuable tool for research in microbiology and infectious diseases. It can be utilized in studies focused on the mechanisms of bacterial resistance and the development of novel antimicrobial agents. -
Bacterial Inhibitor
Citreamicin alpha is a potent bacterial inhibitor demonstrated to exhibit significant antimicrobial activity against a range of Gram-positive cocci. In vitro studies reveal that MIC values for Staphylococci range from 0.12-4.0 μg/ml, and for Streptococcus pyogenes, they range from 0.03-0.12 μg/ml. While Citreamicin alpha shows superior efficacy compared to ampicillin, amoxicillin, and ceftriaxone, it exhibits comparable effects to vancomycin. Its effectiveness against various strains makes it a valuable reagent for research in antibiotic development and resistance studies. -
FgGpmk1 Inhibitor
FgGpmk1-IN-1 is a selective inhibitor of the Fusarium graminearum mitogen-activated protein kinase (FgGpmk1), exhibiting an EC50 value of 3.46 μg/mL. This compound is valuable for investigating the biological role of FgGpmk1 in fungal pathogenesis and offers potential applications in the study of plant-fungal interactions. Researchers can utilize FgGpmk1-IN-1 to explore therapeutic strategies against Fusarium-related diseases. -
Bacterial Inhibitor
Aniline-MPB-amino-C3-PBD is a cytotoxic agent targeting bacterial cells through minor-groove binding of DNA. This sequence-selective compound serves as an effective payload for antibody-drug conjugates (ADCs), enhancing their therapeutic efficacy. Its antimicrobial properties make it a valuable tool for research in bacterial inhibition and related applications. -
Bacterial Inhibitor
Py-MPB-amino-C3-PBD is a cytotoxic agent that functions as a bacterial inhibitor. This compound serves as a payload for antibody-drug conjugates (ADCs) and exhibits significant antimicrobial activity. Its unique structure, characterized by a non-alkylating group, makes it a valuable tool for research applications aimed at targeting bacterial infections and developing therapeutics in the field of microbiology. -
SARS-CoV-2 Inhibitor
TFMU-ADPr is a selective reporter substrate that targets the SARS-CoV-2 Macro1 protein, displaying an IC50 of 0.59 μM. This compound emits fluorescence at 502 nm (or 495 nm) upon enzymatic hydrolysis by Poly(ADP-ribose) Glycohydrolase (PARG) and ADP-ribosylhydrolase 3. TFMU-ADPr binds to the ADPr-binding site of Macro1, providing a robust method for assessing the activity of poly(ADP-ribose) hydrolases. Its applications extend to evaluating small-molecule inhibitors under in vitro conditions, investigating ADP-ribosyl catabolic enzyme mechanisms, and detecting PAR hydrolase activity in whole-cell lysates, making it a valuable tool for COVID-19-related research. -
Bacterial Inhibitor
Resazurin sodium is a non-toxic, stable redox indicator that targets bacterial activity through its membrane-permeable properties. It serves as a vital tool for assessing cell viability, proliferation, and toxicity in various cell types, including human, plant, animal, bacterial, and fungal cells. Upon reduction, Resazurin sodium transforms into Resorufin, a highly fluorescent compound, enabling sensitive detection and quantification of cellular processes under fluorescent microscopy or spectrophotometry. -
SARS-CoV Inhibitor
Direct Violet 1 is an azo dye that functions as an inhibitor of the spike protein-ACE2 interaction in SARS-CoV-2, exhibiting IC50 values ranging from 1.47 to 2.63 μM. This compound serves as a valuable tool for investigating viral entry mechanisms and studying protein-protein interactions related to SARS-CoV-2. Its application may extend to antiviral research and the development of therapeutic strategies targeting COVID-19. -
Bacterial Inhibitor
4-Methylherniarin, a coumarin derivative, exhibits antibacterial activity by effectively inhibiting both gram-positive and gram-negative bacterial strains. It demonstrates significant antimicrobial efficacy against B. subtilis and S. sonnei, with IC50 values of 11.76 μg/ml and 13.47 μg/ml, respectively. This compound serves as a valuable tool for research applications focused on combating bacterial infections and elucidating mechanisms of action in microbial resistance. -
Dengue Protease Inhibitor
Carbonic anhydrase inhibitor 16 is a potent dengue protease inhibitor that targets human carbonic anhydrases I and II, exhibiting inhibitory constants (Ki) of 28.5 nM and 2.2 nM, respectively. This compound demonstrates significant biological activity in hindering dengue virus replication by disrupting protease function. It may be utilized in research applications aimed at elucidating mechanisms of dengue virus pathogenesis and developing antiviral therapeutics. -
Bacterial Inhibitor
Procodazole is a potent bacterial inhibitor that enhances immune response, offering protection against various viral and bacterial infections. In addition to its broad-spectrum antibacterial effects, Procodazole demonstrates antiparasitic activity and serves as a carbonic anhydrase inhibitor, contributing to its antitumor properties. This compound is suitable for research applications focused on infectious diseases and cancer biology. -
HIV Inhibitor
ZL0580 is an HIV inhibitor that functions by selectively binding to the BD1 domain of BRD4, leading to epigenetic suppression of the virus. This compound effectively inhibits Tat transactivation and transcription elongation while promoting a repressive chromatin structure at the HIV promoter. ZL0580 is valuable for research applications focused on HIV therapies and the mechanisms of viral transcription regulation. -
Clk1 Inhibitor
CLK1-IN-2 is a potent and metabolically stable inhibitor of CLK1, exhibiting a selectivity for its target with an IC50 value of 1.7 nM. This compound is valuable for research applications focusing on tumor biology, Duchenne muscular dystrophy, and viral infections, including HIV-1 and influenza. CLK1-IN-2 facilitates the study of cellular mechanisms and therapeutic interventions related to these diseases. -
CLK Inhibitor
KH-CB19 is a selective inhibitor of CLK (cdc2-like kinase) with an IC50 of 19.7 nM for CLK1 and 530 nM for CLK3. This compound exhibits antiviral properties, demonstrated by its ability to hinder influenza virus replication, with an IC50 value of 13.6 μM. KH-CB19 serves as a valuable tool for research into CLK-related pathways and antiviral drug development. -
SARS-CoV-2 Inhibitor
SARS-CoV-2 nsp14-IN-3 is an inhibitor of the SARS-CoV-2 N7-Methyltransferase, demonstrating an IC50 value of 3.5 μM. This compound is designed to interfere with the viral methylation process, which is crucial for viral replication and evasion of host immune responses. It serves as a valuable tool in antiviral research and the development of therapeutic strategies targeting SARS-CoV-2. -
SARS-CoV Inhibitor
SARS-CoV-2-IN-7 is a potent inhibitor of the SARS-CoV virus, demonstrating significant antiviral activity with an IC50 value of 844 nM in SARS-CoV-2-infected Vero E6 cells. This compound is primarily utilized in research applications aimed at understanding viral replication processes and developing effective therapeutics against SARS-CoV-2. Its efficacy makes it a valuable tool for studying COVID-19 and potential antiviral strategies. -
SARS-CoV Inhibitor
Bonducellpin D is a furanoditerpenoid lactone that acts as an inhibitor of SARS-CoV and MERS-CoV main proteases (Mpro). With Ki values of 467.11 nM and 284.86 nM for SARS-CoV and MERS-CoV, respectively, it demonstrates broad-spectrum antiviral activity. Additionally, Bonducellpin D exhibits moderate anti-cancer activity in vitro, making it a valuable compound for research into both viral inhibition and cancer therapeutics. -
SARS-CoV Inhibitor
SSAA09E3 is a SARS-CoV entry inhibitor that effectively blocks the entry of SARS/HIV pseudotyped viruses, demonstrating an EC50 of 9.7 μM in 293T cells. Additionally, it has shown significant antiviral activity against SARS-CoV infection in Vero cells, with an EC50 of 0.15 μM. This compound is valuable for research applications aimed at understanding viral entry mechanisms and developing antiviral strategies against SARS-CoV. -
SARS-CoV-2 Inhibitor
AT-9010 triethylamine is a tri-phosphate active metabolite of AT-527 that functions as a potent inhibitor of the NiRAN enzyme, an essential target for viral replication in SARS-CoV-2. It exhibits significant antiviral activity by effectively inhibiting the replication of SARS-CoV-2, making it a valuable tool for research on COVID-19 and potential therapeutic strategies against coronavirus infections. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-15 is a potent inhibitor of SARS-CoV-2, exhibiting an IC50 of 0.49 μM. This niclosamide analogue demonstrates enhanced stability in human plasma and liver S9 enzyme assays compared to its predecessor, which may improve its bioavailability and half-life upon oral administration. SARS-CoV-2-IN-15 is suitable for research applications focused on antiviral drug development and the elucidation of SARS-CoV-2 infection mechanisms. -
SARS-CoV-2 Inhibitor
Cleistanthin B is a potent inhibitor of SARS-CoV-2, demonstrating anti-viral activity with an EC50 of 6.51 µM in Vero cells. This orally active arylnaphthalene lignan lactone glycoside also exhibits notable antitumor, diuretic, and antihypertensive properties in vivo, making it a versatile compound for various research applications in virology and pharmacology. -
SARS-CoV-2 PLpro Inhibitor
GZNL-P36 is a potent inhibitor of SARS-CoV-2 papain-like protease (PLpro) with an IC50 of 6.45 nM, demonstrating effective inhibition of SARS-CoV and its variants with EC50 values ranging from 58.2 nM to 2.66 µM. In pharmacokinetic studies conducted in CD-1 mice, GZNL-P36 achieved a peak plasma concentration (Cmax) of 549 ng/mL, a half-life (T1/2) of 1.45 hours, and a bioavailability of 74.7%. This compound exhibits notable antiviral activity in SARS-CoV-2 XXB.1 infections, positioning it as a valuable tool in therapeutic research against COVID-19. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-78 is an inhibitor of the nsp14 protein of SARS-CoV-2, specifically targeting its N7 methyltransferase activity. This compound demonstrates significant antiviral properties and is valuable for research applications in understanding and mitigating SARS-CoV-2 infection. Its mechanism of action makes it a pertinent tool for studying viral replication and pathogenesis, as well as the development of potential therapeutic strategies against COVID-19. -
SARS-CoV-2 Inhibitor
ZINC000104379474 is a potent inhibitor of SARS-CoV-2 endoribonuclease. It exhibits significant antiviral activity, making it a valuable tool in the study of SARS-CoV-2 replication mechanisms. This compound is particularly relevant for research focused on COVID-19 therapeutics and the development of novel antiviral strategies. -
SARS-CoV-2 Nsp14 Inhibitor
SARS-CoV-2 nsp14-IN-2 is a selective inhibitor of SARS-CoV-2 Nsp14 methyltransferase, exhibiting an IC50 value of 0.093 µM. This compound demonstrates significant antiviral activity and is stable in plasma and liver S9 fractions. SARS-CoV-2 nsp14-IN-2 is valuable for research applications focusing on COVID-19 and the exploration of therapeutic strategies targeting viral replication mechanisms. -
SARS-CoV Inhibitor
SARS-CoV MPro-IN-1 is a covalent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 of 40 nM. This compound demonstrates significant anti-SARS-CoV-2 activity in cell culture, with an EC50 of 0.33 μM. SARS-CoV MPro-IN-1 is suitable for research applications focused on COVID-19 and related viral pathogenesis. -
SARS-CoV-2 Inhibitor
10-Hydroxyaloin A is a potent inhibitor of SARS-CoV-2, specifically targeting the main protease (Mpro) of the virus. This compound demonstrates significant binding affinity to the active site of Mpro, which is crucial for viral replication. 10-Hydroxyaloin A is of particular interest in research applications focused on antiviral drug development and understanding the mechanisms of SARS-CoV-2 inhibition. -
SARS-CoV-2 3CLpro Inhibitor
3CPLro-IN-1 is a potent, orally active inhibitor of the SARS-CoV-2 3CLpro with an IC50 of 5.65 μM. 3-Chymotrypsin-like cysteine protease (3CLpro) plays a critical role in viral replication, making it a significant target for therapeutic intervention against COVID-19. This compound is suitable for research applications focused on developing antiviral strategies and studying the mechanistic pathways of viral replication. -
SARS-CoV-2 Inhibitor
Amb929 is a selective inhibitor targeting the nsp3 protein of SARS-CoV-2, demonstrating significant antiviral activity. It effectively inhibits SARS-CoV-2-mNG replication in VeroE6 cells with an EC50 of 34.7 µM and has a moderate cytotoxicity profile, with a CC50 of 281 µM. Additionally, Amb929 shows effectiveness in suppressing viral replication in Human Airway Epithelium (HAE) models, making it a valuable tool for research on COVID-19 and therapeutic development. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2-IN-35 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro), demonstrating a Ki value of 12.1 nM. This compound serves as a valuable tool for investigating the antiviral mechanisms and therapeutic strategies in COVID-19 research. Its oral bioactivity allows for flexible in vivo studies, facilitating the exploration of potential treatments against SARS-CoV-2. -
SARS-CoV-2Inhibitor
SARS-CoV-2-IN-43 is a potent inhibitor of SARS-CoV-2 replication, displaying significant antiviral activity. This compound is valuable for research applications aimed at understanding and mitigating SARS-CoV-2 infection. Its mechanism of action targets key processes in viral replication, making it a crucial tool for studies in virology and therapeutic development against COVID-19. -
SARS-CoV-2 Mpro Inhibitor
AB-343 is a selective covalent inhibitor targeting the main protease (Mpro) of SARS-CoV-2, exhibiting an IC50 of 8 nM and a Ki of 2.8 nM. This compound effectively inhibits the Mpro of SARS-CoV-2 and other coronaviruses, demonstrating activity against certain resistant variants. AB-343 is suitable for research applications focused on therapeutic strategies for coronavirus infection-related diseases. -
Macropinocytosis inhibitor
Virapinib is a potent macropinocytosis inhibitor that demonstrates significant antiviral activity. It effectively inhibits viral entry of a broad range of viruses, including SARS-CoV-2, monkeypox virus, tick-borne encephalitis virus, and Ebola pseudotyped vesicular stomatitis virus, while also enhancing Dengue Virus infection. By obstructing macropinocytosis, Virapinib reduces syncytium formation in SARS-CoV-2-infected cells and hinders the cellular entry of SARS-CoV-2 variants. This compound is valuable for research focused on viral pathogenesis and therapeutic evaluations related to COVID-19 and other viral infections. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-1 (compound 16b-3) is a potent and selective irreversible inhibitor of the SARS-CoV-2 main protease (Mpro), demonstrated by an IC50 of 116 nM. This compound serves as a valuable tool in research targeting SARS-CoV-2, facilitating investigations into viral replication and pathogenesis. Its mechanistic profile makes it suitable for studies aimed at developing antiviral strategies against COVID-19. -
SARS-CoV-2 Mpro Iinhibitor
GC-78-HCl is a nonpeptidic inhibitor of the SARS-CoV-2 main protease (Mpro), exhibiting an IC50 of 0.19 μM. This compound demonstrates significant antiviral activity and has been characterized by favorable pharmacokinetic properties. It is a valuable reagent for research aimed at exploring therapeutic strategies against SARS-CoV-2 and related coronaviruses. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-66 is a vitamin K derivative and a potent inhibitor of SARS-CoV-2. It exhibits an EC50 value of 70.8 μM in Vero E6/TMPRSS2 cell lines, demonstrating significant antiviral activity. This compound can be utilized in research focused on the development of therapeutic strategies against SARS-CoV-2 infection. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-100 is a potent inhibitor targeting SARS-CoV-2, exhibiting broad-spectrum antiviral activity against multiple variants of the virus. This compound demonstrates synergistic effects when used in combination with Nirmatrelvir, potentially mitigating the risk of antiviral drug resistance. It is suitable for research applications focused on COVID-19 therapeutics and viral replication studies. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-76 is a specific inhibitor of the nsp14 viral cap N7 methyltransferase and PLpro, targeting the severe acute respiratory syndrome coronavirus (SARS-CoV-2). This compound demonstrates significant antiviral activity by disrupting key enzymatic processes essential for viral replication. It is a valuable tool for research applications focused on understanding SARS-CoV-2 pathogenesis and developing therapeutic strategies against COVID-19.
